Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Haanen, John, Ernstoff, Marc, Wang, Yinghong, Menzies, Alexander, Puzanov, Igor, Grivas, Petros, Larkin, James, Peters, Solange, Thompson, John, Obeid, Michel
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Commentary
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7295425/
https://ncbi.nlm.nih.gov/pubmed/32532839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000604
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi